Skip to main content
Premium Trial:

Request an Annual Quote

Clarification: Mar 4, 2005

Premium

The article entitled “PRG Concludes Ion Traps, Software Less Reliable for De Novo Peptide Sequencing” in the Feb. 11 issue of ProteoMonitor should have mentioned the purpose of the Proteomics Research Group study. The article neglected to mention that the results reported in the article did not represent the core aim of the study.

According to a letter e-mailed to ProteoMonitor on Feb. 24 by the Association of Biomolecular Research Facilities, “[t]he purpose of [the] study was to evaluate the capabilities of core laboratories to determine the sequences of peptides not found in any published database. The main findings of our study relate to the difficulty of de novo peptide sequencing, the importance of high mass accuracy for obtaining good results, the benefit of using multiple approaches, and the shortcomings of current software.

“The study was not designed to compare different types of instruments, as the headline of your article suggests. While our results showed some differences in the de novo sequencing results for different instrument types, we clearly noted that the number of each type of instrument was too small to draw conclusions, and that we did not control for operator expertise.”

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.